Voss MH, Feldman DR, Bosl GJ, Motzer RJ. A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am. 2011;25(3):557–76.

Article  PubMed  PubMed Central  Google Scholar 

Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–8.

Article  CAS  PubMed  Google Scholar 

Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J, Oliver T. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol. 2007;18(5):925–30.

Article  CAS  PubMed  Google Scholar 

Shamash J, Oliver RT, Ong J, et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol. 1999;10:685–92.

Article  CAS  PubMed  Google Scholar 

Kollmannsberger Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plusoxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108–14.

Article  CAS  PubMed  Google Scholar 

Pectasides M, Pectasides Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15:493–7.

Article  CAS  PubMed  Google Scholar 

De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur urol. 2006;50:1032–8.

Article  PubMed  Google Scholar 

Bokemeyer Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German testicular cancer study group. Ann Oncol. 2008;19(3):448–53.

Article  CAS  PubMed  Google Scholar 

FizaziCulineChen KSI. Oxaliplatin in non-seminomatousgerm-cell tumors. Ann Oncol. 2004;15:1295–9.

Article  Google Scholar 

Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ celltumors. J Clin Oncol. 1994;12:2277–83.

Article  CAS  PubMed  Google Scholar 

Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007;25:85–90.

Article  CAS  PubMed  Google Scholar 

Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin refractory germ-cell tumor patients: a phase II study. Eur Urol. 2004;46:216–21.

Article  CAS  PubMed  Google Scholar 

Powles T, Shamash J, Berney D, et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German testicular cancer study group. Br J Cancer. 2003;89:1140–1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badreldin W, Krell J, Chowdhury S, Harland SJ, Mazhar D, Harding V, Frampton AE, Wilson P, Berney D, Stebbing J, Shamash J. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach. BJU Int. 2016;117:418–23.

Article  CAS  PubMed  Google Scholar 

Kurobe M, Kawai K, Oikawa T, et al. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor. J Cancer Res Clin Oncol. 2015;141(1):127–33.

Article  CAS  PubMed  Google Scholar 

Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–4.

Article  CAS  PubMed  Google Scholar